Febrile neutropenia and reduced dose intensity in patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP and CNOP.

被引：0
|
作者：
Dale, DC
Crawford, J
Agboola, O
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Duke Univ, Med Ctr, Durham, NC 27706 USA
[3] Univ Rochester, Med Ctr, Rochester, NY 14627 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6599
引用
收藏
页码：582S / 582S
页数：1
相关论文
共 50 条
  • [1] Reduced relative dose intensity (RDI) in patients with aggressive non-Hodgkin's lymphoma (NHL).
    Dale, DC
    Goldschmidt, JH
    Crawford, J
    Lyman, GH
    BLOOD, 2004, 104 (11) : 905A - 906A
  • [2] Dose intensity (DI) chemotherapy improves disease free survival in elderly aggressive non-Hodgkin's lymphoma (NHL) patients treated with conventional CHOP
    Gomez, H
    Santillana, S
    Casanova, L
    Valdivia, S
    Otero, J
    Mas, L
    Vallejos, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 802 - 802
  • [3] Short high-dose CHOP chemotherapy for aggressive non-Hodgkin's lymphoma (NHL).
    Epelbaum, R
    Dann, E
    Drumea, K
    Haim, N
    Ben-Shahar, M
    Faraggi, D
    Rowe, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 584S - 584S
  • [4] Quality of life (QOL) in elderly patients with aggressive non-Hodgkin's lymphoma. (NHL) treated with CHOP.
    Doorduyn, JK
    Buijt, I
    Uyl-de Groot, CA
    van der Holt, B
    Sonneveld, P
    BLOOD, 2001, 98 (11) : 430A - 430A
  • [5] Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
    Lyman, GH
    Delgado, DJ
    CANCER, 2003, 98 (11) : 2402 - 2409
  • [6] A randomized trial comparing intensified CNOP vs. CHOP in patients with aggressive non-Hodgkin's lymphoma
    Pangalis, GA
    Vassilakopoulos, TP
    Michalis, E
    Roussou, P
    Vrakidou, E
    Repousis, P
    Angelopoulou, MK
    Siakantaris, MP
    Korantzis, J
    Symeonidis, A
    Grigorakis, V
    Stefanoudakis, E
    Stamatellou, M
    Bourantas, KL
    Kalmantis, T
    Christopoulos, G
    Kokkinis, G
    Mihalakeas, I
    Papayiannis, A
    LEUKEMIA & LYMPHOMA, 2003, 44 (04) : 635 - 644
  • [7] CNOP (Mitoxantrone) chemotherapy is inferior to CHOP (Doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (Review).
    Bjorkholm, Magnus
    Osby, Eva
    Andersson, Tomas
    Ahlbom, Anders
    BLOOD, 2006, 108 (11) : 689A - 690A
  • [8] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitchan, P
    Swasdikul, D
    LEUKEMIA & LYMPHOMA, 2000, 37 (3-4) : 351 - 360
  • [9] Reduced-dose CHOP therapy for elderly patients with non-Hodgkin's lymphoma
    Mori, M
    Niitsu, N
    Takagi, T
    Tomiyama, J
    Matsue, T
    Nakagawa, Y
    Okamoto, R
    LEUKEMIA & LYMPHOMA, 2001, 41 (3-4) : 359 - 366
  • [10] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of chop chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitjan, P
    Swasdikul, D
    BLOOD, 1998, 92 (10) : 225B - 225B
12345